普洛药业(000739) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥2,122,027,692.91, representing a 16.67% increase year-over-year[2] - Net profit attributable to shareholders was ¥208,725,104.95, up 4.03% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses was ¥169,749,985.78, reflecting a 9.82% increase year-over-year[2] - The company reported a 22.45% increase in operating profit, totaling ¥903,070,746.23, driven by higher sales and gross profit[6] - Total operating revenue for Q3 2021 reached CNY 6,399,153,386.70, an increase of 10.1% compared to CNY 5,810,594,633.35 in the same period last year[13] - Net profit attributable to the parent company was CNY 762,133,599.42, up from CNY 630,118,433.62, representing a growth of 20.9% year-over-year[14] - Operating profit for the period was CNY 903,070,746.23, compared to CNY 737,500,990.95 in the previous year, indicating a rise of 22.5%[13] - Total operating costs for the period were CNY 5,585,830,987.06, compared to CNY 5,195,242,655.36, indicating an increase of 7.5%[13] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥8,786,552,584.33, a 17.24% increase from the previous year[2] - The equity attributable to shareholders increased to ¥4,866,465,554.98, marking a 10.84% rise compared to the end of the previous year[2] - Total liabilities rose to CNY 3,920,087,029.35, up from CNY 3,104,112,724.02, representing a growth of 26.3%[12] - The company's total current assets as of September 30, 2021, amounted to ¥5,827,751,885.92, an increase from ¥4,917,396,988.87 in the previous year[11] - The total non-current assets increased to ¥2,958,800,698.41 from ¥2,577,390,968.47 year-over-year[11] Cash Flow - The operating cash flow for the year-to-date was ¥660,960,893.14, showing a significant decline of 33.83% year-over-year[2] - The net cash flow from operating activities for Q3 2021 was ¥660,960,893.14, a decrease of 33.9% compared to ¥998,942,728.52 in Q3 2020[16] - Total cash inflow from operating activities amounted to ¥5,029,206,843.86, up 12.4% from ¥4,472,455,219.77 in the same period last year[16] - Cash outflow from operating activities increased to ¥4,368,245,950.72, representing a rise of 25.7% compared to ¥3,473,512,491.25 in Q3 2020[16] - The net cash flow from investing activities was -¥452,030,530.24, a significant decline from ¥186,031,436.43 in Q3 2020[16] - Cash inflow from investing activities totaled ¥169,243,259.74, down 70.7% from ¥576,541,842.14 in the previous year[16] - Cash outflow from investing activities increased to ¥621,273,789.98, up 59.1% from ¥390,510,405.71 in Q3 2020[16] - The net cash flow from financing activities was -¥153,091,066.39, compared to -¥26,791,420.46 in Q3 2020[17] - Cash inflow from financing activities reached ¥785,100,000.00, a substantial increase from ¥230,100,000.00 in the same quarter last year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,248[8] - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of shares, totaling 330,941,729 shares, with 156,000,000 shares pledged[8] - The company has a total of 32,664,016 shares held under the first employee stock ownership plan[9] Research and Development - Research and development expenses increased by 18.12% to ¥321,495,631.04, indicating a focus on innovation[6] - Research and development expenses increased to CNY 321,495,631.04, up from CNY 272,178,180.32, reflecting a growth of 18.1%[13] Inventory and Accounts Payable - Inventory increased to ¥1,146,406,041.90 from ¥1,086,181,605.07 in the previous year[11] - The company reported a total of ¥1,341,874,527.90 in accounts payable, compared to ¥682,462,979.39 in the previous year[11] Audit Information - The company did not undergo an audit for the Q3 2021 report[18]